Transdiagnostic Psychiatry in 2026: From Diagnostic Categories to Mechanism-Based Formulation
Aug 12, 2026
The most difficult psychiatric cases are often difficult precisely because the diagnostic label does not adequately organize the clinical picture.
A patient may meet criteria for major depressive disorder, generalized anxiety disorder, and PTSD while presenting with a relatively coherent pattern of threat sensitivity, avoidance, sleep disruption, repetitive negative thinking, and interpersonal hypervigilance. Another patient may carry several diagnoses across different periods of treatment, although the underlying vulnerabilities remain remarkably stable. A third may satisfy criteria for a disorder while showing only a subset of the mechanisms usually associated with that diagnosis.
This creates a practical problem for clinicians. Diagnostic categories remain necessary, but they do not always provide the most useful level of explanation for treatment planning.
The current movement toward transdiagnostic psychiatry is therefore less about replacing DSM or ICD and more about asking what should sit alongside the diagnosis. In 2026, this includes dimensional psychopathology, cross-cutting symptom assessment, mechanistic formulation, symptom-network models, clinical staging, and increasingly individualized measurement.
The important question is no longer simply whether psychiatric disorders have boundaries. It is whether those boundaries are always the most clinically informative way to understand an individual patient.
Where Categorical Diagnosis Becomes Clinically Insufficient
The strongest argument for transdiagnostic thinking comes from patients whose presentations cross conventional diagnostic boundaries.
Comorbidity is often structural rather than incidental
When depression, anxiety, trauma symptoms, substance misuse, insomnia, and somatic symptoms occur together, clinicians often approach them as separate diagnoses. That can be appropriate for documentation, but it can produce a fragmented formulation.
Suppose a patient has major depressive disorder, panic disorder, and insomnia. Treating each diagnosis independently could result in three parallel treatment plans.
A formulation focused on mechanisms might instead identify:
perceived threat → physiological arousal → catastrophic interpretation → avoidance → reduced activity → sleep disruption → increased emotional vulnerability
The resulting treatment plan may target a smaller number of processes that contribute to several symptom clusters simultaneously.
This does not make the diagnoses irrelevant. It changes the level at which the clinical problem is organized.
Diagnostic heterogeneity is equally important
The same diagnosis can conceal substantially different clinical configurations.
Two patients with major depressive disorder may have very different dominant features. One may be characterized by anhedonia, psychomotor slowing, and reduced reward sensitivity. Another may have severe anxiety, rumination, irritability, interpersonal sensitivity, and insomnia.
Calling both presentations "moderate major depressive disorder" is diagnostically legitimate but therapeutically incomplete.
The formulation needs another layer.
The Shift From Syndromes to Psychopathology Dimensions
One of the most important developments in contemporary psychiatric science is the move toward describing psychopathology at multiple levels.
Rather than treating a disorder as a unitary construct, dimensional models examine patterns of symptom covariance, traits, severity, and broader spectra of psychopathology.
HiTOP is particularly relevant here because it organizes psychopathology hierarchically, allowing clinicians and researchers to move between broad dimensions and more specific symptom configurations.
This approach is potentially valuable in patients with extensive comorbidity because it can reveal that apparently separate diagnoses share a higher-order structure.
For example, depressive symptoms, generalized anxiety, panic, and certain trauma-related symptoms may all contribute to an individual's broader internalizing burden.
That does not mean they should all be clinically collapsed into one condition. It means the clinician can distinguish between:
the syndrome that is currently being treated
and
the broader liability within which that syndrome is occurring.
This distinction becomes particularly useful longitudinally.
A patient may no longer meet criteria for a depressive episode but continue to show high negative affectivity, interpersonal sensitivity, and repetitive negative thinking. If the formulation focuses exclusively on categorical status, clinically meaningful vulnerability can disappear from view.
HiTOP and RDoC Address Different Problems
Two major frameworks frequently appear in discussions of transdiagnostic psychiatry, but they should not be treated as interchangeable.
HiTOP primarily addresses the empirical organization of psychopathology. It asks how symptoms and maladaptive traits cluster and how broad spectra can be identified from those patterns.
RDoC approaches psychopathology from a different direction, emphasizing neurobehavioral systems and constructs that can be investigated across traditional diagnoses.
The distinction matters clinically.
A HiTOP-oriented formulation might ask:
How does this patient's symptom profile fit within broader internalizing, externalizing, thought-disorder, or somatic dimensions?
An RDoC-informed research question might ask:
Which threat, reward, cognitive, social, or arousal-regulatory systems are implicated in this patient's difficulties?
Neither framework by itself provides a complete clinical formulation.
The more realistic direction is integration: dimensional psychopathology can describe the clinical phenotype, while mechanistic models can investigate the systems potentially contributing to it.
Recent work has continued to explore how HiTOP dimensions and RDoC constructs can be mapped onto shared biological and behavioral mechanisms, reinforcing the possibility of connecting clinical dimensional models with mechanistic research.
The Increasing Importance of Cross-Cutting Symptoms
The transdiagnostic perspective is already visible within contemporary clinical assessment.
DSM-5-TR includes cross-cutting measures designed to identify symptoms that may be relevant across multiple diagnostic categories. These include domains such as depression, anxiety, anger, sleep disturbance, repetitive thoughts and behaviors, substance use, and somatic symptoms.
This is clinically useful because a conventional diagnostic interview can unintentionally narrow attention.
Once a clinician has identified major depressive disorder, for example, it is easy to spend most of the assessment documenting depressive symptoms while giving insufficient attention to sleep, substance use, repetitive thoughts, anger, or other dimensions that may materially affect prognosis and treatment.
Cross-cutting assessment creates a structured opportunity to ask:
What else is clinically active that the primary diagnosis does not adequately capture?
The purpose is not to produce a longer problem list.
It is to identify domains that could change the formulation.
Mechanisms Matter More Than Labels When Planning Treatment
A transdiagnostic formulation becomes clinically useful only when it identifies processes that can actually be modified.
Several mechanisms have attracted particular attention.
Negative affectivity
Negative affectivity is relevant across a wide range of internalizing and personality presentations.
The clinically useful question is not simply whether negative affect is elevated, but how the patient responds to it.
Does distress lead to avoidance? Rumination? Reassurance seeking? Substance use? Interpersonal escalation? Withdrawal?
The same level of emotional distress can produce very different behavioral sequences.
That sequence may matter more for treatment selection than the severity score itself.
Threat sensitivity
Threat processing cuts across anxiety disorders, PTSD, paranoia, some depressive presentations, and several forms of interpersonal dysfunction.
A transdiagnostic formulation should distinguish:
actual environmental threat;
anticipated threat;
ambiguous cues interpreted as threatening;
physiological threat responses;
and secondary fear of the physiological response itself.
This distinction can radically change intervention.
A patient with panic disorder who fears bodily sensations requires a different formulation from a patient whose panic occurs primarily in response to interpersonal rejection, even if both meet the same diagnostic criteria.
Repetitive negative thinking
Rumination and worry have traditionally been assigned to different diagnostic territories.
A process-based formulation recognizes the overlap in the underlying pattern: repetitive, difficult-to-disengage negative cognition.
The content remains clinically important, but the process may be the more transferable treatment target.
For some patients, reducing repetitive negative thinking may influence depressive symptoms, anxiety, sleep, concentration, and interpersonal functioning simultaneously.
Anhedonia and reward dysfunction
Anhedonia has increasingly attracted transdiagnostic attention because reduced reward responsiveness appears across depressive disorders and other psychiatric conditions.
Importantly, anhedonia should not be treated as synonymous with "not enjoying things."
A more precise assessment distinguishes:
anticipatory pleasure;
consummatory pleasure;
motivation;
reward learning;
effort allocation;
and sensitivity to positive feedback.
Two patients reporting "anhedonia" may therefore have very different underlying problems.
One may experience diminished pleasure once engaged in an activity. Another may fail to anticipate that an activity will be rewarding and consequently never initiate it.
Those presentations suggest different intervention targets.
Experiential avoidance
Avoidance is particularly powerful because it often produces immediate relief while maintaining the broader disorder.
The clinical question is:
What experience is the patient attempting not to have?
The answer might be fear, shame, uncertainty, bodily arousal, grief, interpersonal rejection, intrusive thoughts, or perceived loss of control.
Avoidance can therefore appear very differently across PTSD, OCD, panic disorder, depression, substance use, and personality pathology while serving a similar short-term regulatory function.
From “Comorbidity” to Shared Maintaining Processes
The word comorbidity can sometimes obscure more than it clarifies.
Consider a patient with:
PTSD;
major depressive disorder;
generalized anxiety disorder;
insomnia;
and alcohol misuse.
A traditional formulation may list five conditions.
A mechanism-based formulation might identify:
Trauma-related threat sensitivity
↓
Hyperarousal and sleep disruption
↓
Repetitive negative thinking
↓
Avoidance and social withdrawal
↓
Reduced rewarding activity
↓
Depressive symptoms
↓
Alcohol use for short-term emotional regulation
↓
Worsened sleep and emotional instability
The second formulation does not eliminate the diagnoses. It explains their interaction.
That distinction is especially important when treatment is sequenced.
If insomnia, alcohol use, and severe physiological hyperarousal are maintaining the depressive presentation, simply escalating an antidepressant regimen may not address the entire system.
Conversely, if severe anhedonia and motivational impairment are central, behavioral activation and reward-focused interventions may be more relevant than interventions aimed primarily at threat appraisal.
Network Models: Useful Clinical Hypothesis, Not Established Causality
Network approaches have become increasingly influential because they conceptualize symptoms as potentially interacting rather than assuming that every symptom is generated by a single latent disorder.
This creates an appealing clinical possibility.
If insomnia increases irritability, irritability increases interpersonal conflict, interpersonal conflict increases rumination, and rumination worsens insomnia, then intervening at one point in the system might influence several downstream symptoms.
But the clinical interpretation needs to remain cautious.
A network showing a statistically central symptom does not automatically demonstrate that the symptom is causally responsible for the disorder.
This is one of the major issues in current network research.
Recent methodological work has highlighted problems involving cross-sectional data, between-person versus within-person effects, temporal relationships, variable selection, and causal interpretation. Longitudinal research has also demonstrated substantial individual variability in symptom-network structure.
Consequently, a network model should be treated as a clinical hypothesis generator, not a causal map.
The question for the clinician is not:
“Which symptom is statistically central?”
It is:
“Which process appears to be maintaining this patient's difficulties, and what evidence would tell me whether changing it actually changes the system?”
That is a much higher standard.
The Individual Patient Is Not the Average Network
This is particularly important when translating transdiagnostic research into practice.
A population-level association does not automatically describe an individual's psychopathology.
Suppose a large study finds that sleep disturbance is strongly associated with depression.
That does not establish that sleep disturbance is the central maintaining mechanism in every patient with depression.
For one patient, insomnia may be downstream of severe rumination.
For another, it may be caused by medication.
For another, it may be driven by sleep apnea.
For another, it may be a consequence of manic-spectrum activation that fundamentally changes the diagnostic formulation.
Transdiagnostic psychiatry therefore requires individual-level formulation rather than simply applying population-level dimensions to individual patients.
Transdiagnostic Assessment in Clinical Practice
A sophisticated assessment can retain the conventional diagnostic interview while adding several additional questions.
1. What syndrome is present?
Establish the categorical diagnosis and relevant differential diagnoses.
2. What symptoms cut across the presentation?
Assess domains such as sleep, anxiety, anger, repetitive cognition, somatic symptoms, substance use, dissociation, psychosis, and suicidality.
3. What dimensions are elevated?
Consider broader patterns such as negative affectivity, detachment, disinhibition, anankastia, or other clinically relevant traits.
4. What triggers activation?
Identify internal and external antecedents rather than treating symptoms as context-free events.
5. What happens next?
Map the behavioral and cognitive response.
6. What provides short-term relief?
This is often where maintaining mechanisms become visible.
7. What produces long-term cost?
The behavior that reduces distress immediately may be precisely what perpetuates the problem.
8. What changes over time?
Repeated assessment can distinguish stable vulnerabilities from state-dependent symptoms.
This approach can produce a formulation such as:
High negative affectivity + interpersonal threat sensitivity → rumination → avoidance → reduced reinforcement → depressive symptoms.
That formulation is more actionable than a list of diagnostic codes.
Measurement-Based Care Becomes More Valuable, Not Less
A common misconception is that transdiagnostic psychiatry requires increasingly elaborate conceptualization while making measurement less important.
The opposite is more useful.
When clinicians work across dimensions, repeated measurement becomes particularly valuable because treatment progress may occur unevenly across domains.
A patient may show:
a 50% reduction in depressive symptoms;
minimal improvement in insomnia;
persistent anxiety;
improved occupational functioning;
and worsening alcohol use.
A single global judgment of "better" or "not better" would miss this configuration.
DSM-5-TR's assessment resources already support this broader approach through cross-cutting symptom measures, disorder-specific severity measures, disability assessment, and personality inventories.
The objective should not be maximal measurement.
It should be decision-relevant measurement.
A measure belongs in the clinical workflow when its result has the potential to change what the clinician does next.
Transdiagnostic Treatment Does Not Mean One Treatment for Everyone
One of the most important distinctions in the field is between transdiagnostic mechanisms and transdiagnostic protocols.
A transdiagnostic protocol attempts to treat several disorders using a common therapeutic framework.
A mechanism-based approach is more individualized. It asks which processes are active in this particular patient and which intervention is most likely to modify them.
Those are not identical strategies.
A patient with depression and generalized anxiety may benefit from targeting repetitive negative thinking.
Another patient with the same diagnoses may be dominated by severe behavioral avoidance.
A third may have prominent anhedonia and reduced reward sensitivity.
A fourth may have interpersonal threat sensitivity that maintains both anxiety and depressive symptoms.
The diagnosis is identical.
The formulation is not.
This is one reason process-based and mechanism-focused approaches have become increasingly relevant to personalized psychotherapy.
Psychopharmacology Within a Transdiagnostic Framework
Transdiagnostic thinking also has implications for medication management, although it should not be used to bypass diagnostic reasoning.
Psychiatric medications already operate across traditional diagnostic boundaries. The same pharmacological class may be relevant to multiple disorders, while individual patients can differ considerably in response despite sharing a diagnosis.
A transdiagnostic formulation can therefore add information about the target symptom architecture.
For example:
persistent anhedonia may require attention to reward-related symptoms;
severe physiological hyperarousal may alter the treatment priorities;
insomnia may be a treatment target rather than merely a secondary symptom;
impulsivity may have greater clinical significance than depressed mood in a particular patient;
cognitive slowing may affect functional recovery even after mood improves.
However, medication selection still requires diagnostic assessment, exclusion of bipolar-spectrum conditions when relevant, evaluation of psychosis and suicidality, medical review, interaction assessment, prior treatment history, adverse-effect considerations, and patient preferences.
Transdiagnostic reasoning complements these decisions; it does not replace them.
ICD-11 and the Move Toward Dimensional Thinking
The transition to ICD-11 provides an important example of how dimensional thinking can coexist with formal diagnosis.
The ICD-11 personality-disorder model places substantially greater emphasis on severity and prominent trait domains rather than relying exclusively on multiple separate categorical personality disorders.
Clinically, this allows formulation to distinguish between the presence of personality pathology and the specific configuration in which it appears.
The broader implication is important.
Modern classification does not necessarily require a choice between:
categorical diagnosis
and
dimensional formulation.
The two can operate at different levels.
A diagnosis can provide a standardized clinical classification, while dimensions provide additional information about severity, traits, and symptom architecture.
That hybrid model may be more realistic for clinical practice than expecting a single classification system to perform every function.
Where Transdiagnostic Psychiatry Should Not Be Overstated
The field has considerable promise, but several limitations should remain explicit.
Mechanisms are not automatically causes
A process associated with psychopathology is not necessarily the causal driver of that individual's illness.
Transdiagnostic does not mean nonspecific
A useful formulation must become more specific, not less.
"Emotion dysregulation" alone is not a sufficient treatment formulation. The clinician needs to identify what emotion, in what context, through what regulatory strategy, with what consequence.
Network centrality is not proof of therapeutic leverage
A statistically central symptom may not be the most effective intervention target.
Dimensional models can still lose clinically important distinctions
Psychosis, mania, severe suicidality, catatonia, substance intoxication, and other high-risk states require diagnostic and safety reasoning that cannot be reduced to a general dimensional score.
Research frameworks should not be treated as billing systems
HiTOP and RDoC can influence conceptualization and research without replacing the diagnostic and coding systems required in clinical practice.
More formulation is not necessarily better formulation
A 20-page mechanistic formulation is not inherently superior to a concise one.
The best formulation is the one that changes clinical decisions.
A Practical Transdiagnostic Formulation Template
For complex cases, clinicians can structure the formulation around six questions:
Clinical question | What to identify |
|---|---|
What is present? | Diagnoses, symptoms, severity, impairment |
What cuts across diagnoses? | Shared symptoms, traits, dimensions |
What activates the problem? | Triggers, contexts, physiological states |
What maintains it? | Avoidance, rumination, reinforcement, sleep disruption, interpersonal cycles |
What protects against deterioration? | Relationships, routines, coping strategies, treatment adherence, functioning |
What should change first? | Highest-value modifiable process |
The last question is arguably the most important.
A formulation is useful when it produces a treatment hierarchy.
Clinical Example: Same Diagnoses, Different Treatment Targets
Consider two patients who both meet criteria for major depressive disorder and generalized anxiety disorder.
Patient A
The dominant pattern is:
worry → insomnia → fatigue → reduced concentration → work impairment → self-criticism → more worry
The most important transdiagnostic targets may be repetitive negative thinking, sleep disruption, behavioral withdrawal, and cognitive responses to perceived failure.
Patient B
The dominant pattern is:
interpersonal criticism → shame → withdrawal → reduced social reinforcement → anhedonia → depression → increased sensitivity to rejection
Although the diagnoses are identical, the mechanism is different.
The second patient may require greater emphasis on interpersonal processes, shame, behavioral re-engagement, and social functioning.
This illustrates why diagnosis and formulation should not compete.
The diagnosis establishes the clinical syndrome.
The formulation determines what is keeping that syndrome active in this person.
What Changes for Clinicians in 2026?
The practical consequence of transdiagnostic psychiatry is not that clinicians need to abandon conventional psychiatric assessment.
It is that assessment can become more layered.
Instead of stopping after:
"The patient meets criteria for MDD."
the clinician can continue:
"What dimensions are most elevated?"
"Which symptoms appear to be interacting?"
"Which mechanisms are maintaining functional impairment?"
"Which processes have changed with treatment?"
"What remains active after the primary syndrome improves?"
This approach also improves longitudinal care.
If the patient moves from depression to remission, the clinician can continue monitoring the vulnerabilities that may predict recurrence rather than treating remission as the end of the formulation.
Likewise, when a patient carries multiple diagnoses, the clinician can distinguish between parallel problems and interdependent processes.
That distinction can influence treatment sequencing, measurement, psychotherapy referral, medication management, and coordination between providers.
The Direction of Psychiatric Formulation
The likely future of psychiatry is not a complete victory of dimensions over diagnoses.
A more plausible model is layered clinical reasoning:
Diagnosis
What syndrome is currently present?
↓
Severity and dimensions
How extensive is the psychopathology, and which traits or symptom domains are prominent?
↓
Mechanisms
What processes appear to generate or maintain the symptoms?
↓
Context
What environmental, developmental, interpersonal, medical, and behavioral factors influence those processes?
↓
Treatment targets
Which mechanisms are sufficiently modifiable and clinically important to prioritize?
This is more compatible with the complexity of real psychiatric practice than either extreme: treating DSM/ICD categories as complete explanations or abandoning diagnostic categories entirely.
Conclusion
Transdiagnostic psychiatry has become increasingly relevant because the boundaries between psychiatric disorders are often less clinically stable than diagnostic manuals imply.
The important development in 2026 is not a movement toward eliminating diagnosis. It is a movement toward adding explanatory depth to diagnosis.
HiTOP provides a dimensional account of psychopathology. RDoC approaches psychopathology through neurobehavioral systems. Network models examine interactions among symptoms. ICD-11 incorporates dimensionality more explicitly in areas such as personality pathology. DSM-5-TR already provides cross-cutting assessment tools that allow clinicians to examine symptom domains extending beyond a primary diagnosis.
For clinical practice, however, the most useful application is formulation.
A patient with depression and anxiety does not necessarily require the same treatment as another patient with depression and anxiety. A patient with PTSD and depression may have avoidance as the dominant maintaining process, while another may be driven more strongly by anhedonia, sleep disruption, interpersonal threat, or repetitive negative thinking.
The diagnostic category tells the clinician where the patient fits within the classification system.
The transdiagnostic formulation asks a more clinically demanding question:
What is happening across diagnostic boundaries that explains why this patient's symptoms persist, interact, and respond—or fail to respond—to treatment?
That is where transdiagnostic psychiatry has its greatest value: not in replacing diagnosis, but in making psychiatric formulation more individualized, longitudinal, mechanistic, and clinically actionable.
FAQ
What is the clinical value of HiTOP?
HiTOP can help clinicians conceptualize psychopathology dimensionally, particularly when patients present with extensive comorbidity or symptoms that cross conventional diagnostic boundaries.
Is RDoC used to diagnose patients?
No. RDoC is primarily a research framework for investigating neurobehavioral systems relevant to psychopathology. It should not be treated as a replacement for clinical diagnostic systems.
Are symptom networks ready to guide individual treatment?
Not as a standalone method. Network approaches can generate useful hypotheses about symptom interactions, but current methodological limitations mean that statistical centrality should not automatically be interpreted as causal importance or therapeutic leverage.
What are common transdiagnostic treatment targets?
Frequently studied targets include negative affectivity, threat sensitivity, repetitive negative thinking, avoidance, emotion regulation, anhedonia and reward processing, cognitive control, sleep disturbance, and interpersonal processes.
Does transdiagnostic treatment mean using the same therapy for every disorder?
No. A transdiagnostic approach can use shared therapeutic principles while still selecting interventions according to the mechanisms maintaining an individual patient's symptoms.
Why is transdiagnostic assessment useful when a diagnosis is already established?
Because the diagnosis may not capture symptom dimensions, functional impairment, comorbid processes, or maintaining mechanisms that determine treatment response. Cross-cutting assessment can identify clinically relevant domains that would otherwise receive insufficient attention.
References
If you’re ready to spend less time on documentation and more on therapy, get started with a free trial today
Not medical advice. For informational use only.
Outline
More articles
